4DMT shoots for a $75M IPO, its second attempt to go public with its gene therapy vector programs
Just a few months after withdrawing its IPO filing, 4D Molecular Therapeutics is seeking to go public once again.
The Emeryville, CA-based company
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
